Add-On Prostaglandin E in Venovenous Extracorporeal Membrane Oxygenation: A Randomized, Double-Blind, Placebo-controlled Pilot Trial.

Prostaglandin E (alprostadil; PGE), in addition to low-dose unfractionated heparin, increases the biocompatibility of extracorporeal systems and enhances the efficacy of artificial organs without increasing bleeding risk. We investigated the safety and efficacy of PGE in adults receiving venovenous extracorporeal membrane oxygenation (ECMO). This study was a randomized, double-blind, placebo-controlled phase II pilot trial at two medical intensive care units at the Medical University of Vienna, Austria. Adults with venovenous ECMO were randomly assigned to receive an intravenous infusion of 5 ng/kg/min PGE or placebo (0.9% saline) in addition to standard anticoagulation with unfractionated heparin. The primary outcome was the rate of transfused packed red blood cells per ECMO day. Secondary outcomes were the incidence of and time to clinically overt bleeding and thromboembolic events. A subgroup analysis included only patients with coronavirus disease (COVID-19). Between September 2016 and April 2021, of 133 screened patients, 50 patients were randomized, of whom 48 received the assigned study medication (24 per group). The transfusion rate was similar between groups (0.41 vs. 0.39;  = 0.733). PGE was associated with fewer thromboembolic events (7 vs. 16;  = 0.020) and longer thromboembolism-free time (hazard ratio [HR], 0.302;  = 0.01), fewer clinically overt bleeding events (2 vs. 11;  = 0.017), and longer bleeding-free time (HR, 0.213;  = 0.047). In patients with COVID-19 ( = 25), the HRs for clinically overt bleeding and thromboembolism were 0.276 (95% confidence interval, 0.035-2.186) and 0.521 (95% confidence interval, 0.149-1.825), respectively. Add-on treatment with PGE was safe but did not meet the primary endpoint of reducing the rate of red blood cell transfusions in patients receiving venovenous ECMO. Larger studies need to evaluate the safety and efficacy of additional PGE in ECMO. Clinical trial registered with EudraCT (2015-005014-30) and www.clinicaltrials.gov (NCT02895373).